ONESOURCE.NS Onesource Specialty Pharma Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 32479 | 14390 | 44.31% |
| 2026-08-27 | 315066 | 185796 | 58.97% |
| 2026-08-26 | 130037 | 65956 | 50.72% |
| 2026-08-25 | 60036 | 24010 | 39.99% |
| 2026-08-24 | 80345 | 38100 | 47.42% |
| 2026-08-21 | 50188 | 28372 | 56.53% |
| 2026-08-20 | 73142 | 33423 | 45.70% |
| 2026-08-19 | 67691 | 31530 | 46.58% |
| 2026-08-18 | 231526 | 156119 | 67.43% |
| 2026-08-17 | 104753 | 58162 | 55.52% |
| 2026-08-14 | 239351 | 134570 | 56.22% |
| 2026-08-13 | 98933 | 46690 | 47.19% |
| 2026-08-12 | 135574 | 79576 | 58.70% |
| 2026-08-11 | 356777 | 193318 | 54.18% |
| 2026-08-10 | 230127 | 106792 | 46.41% |
| 2026-08-07 | 151582 | 82244 | 54.26% |
| 2026-08-06 | 200704 | 141052 | 70.28% |
| 2026-08-05 | 147709 | 75259 | 50.95% |
| 2026-08-04 | 268093 | 120232 | 44.85% |
| 2026-08-03 | 291606 | 151019 | 51.79% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers ONESOURCE.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | PRONOMZ VENTURES LLP | Promoter Group | Buy | Market Purchase | 33906 | 40484442 | 2.37% | XBRL |
| 06 Feb 2026 | Tenshi Pharmaceuticals Private Limited | Promoters | Buy | Market Purchase | 75000 | 87133500 | 18.15% | XBRL |
| 06 Feb 2026 | TENSHI PHARMACEUTICALS PRIVATE LIMITED | Promoters | Buy | Market Purchase | 205000 | 238775533 | 18.33% | XBRL |
| 06 Feb 2026 | PRONOMZ VENTURES LLP | Promoter Group | Buy | Market Purchase | 45000 | 50950494 | 2.41% | XBRL |
| 06 Feb 2026 | TENSHI PHARMACEUTICALS PRIVATE LIMITED | Promoters | Buy | Market Purchase | 85000 | 10208119 | 18.40% | XBRL |
| 06 Feb 2026 | Tenshi Pharmaceuticals Private Limited | Promoters | Buy | Market Purchase | 200000 | 20779011 | 18.09% | XBRL |
| 16 Jun 2025 | Pronomz Ventures LLP | Promoter Group | Sell | Off Market | 5102548 | 10087737396 | 2.34% | XBRL |
| 10 Feb 2025 | Sajitha Pillai | Promoter Group | Sell | Market Sale | 5000 | 7739200 | 0.03% | XBRL |
| 06 Feb 2025 | Padmakumar Karunakaran Pillai | Promoter Group | Sell | Market Sale | 50000 | 77936343 | 0.04% | XBRL |
| 06 Feb 2025 | Vineetha Mohankumar Pillai | Promoter Group | Sell | Market Sale | 47500 | 74355589 | 0.04% | XBRL |
| 06 Feb 2025 | Hemalatha Pillai | Promoter Group | Sell | Market Sale | 12000 | 18955497 | 0.02% | XBRL |
| 06 Feb 2025 | Pronomz Ventures LLP | Promoter Group | Sell | Market Sale | 582524 | 899999580 | 6.80% | XBRL |
| 06 Feb 2025 | Tenshi Pharmaceuticals Private Limited | Promoters | Sell | Market Sale | 3300970 | 5056240975 | 17.94% | XBRL |
| 06 Feb 2025 | Neeraj Sharma | Director | Sell | Market Sale | 20000 | 29742950 | 0.12% | XBRL |
| 06 Feb 2025 | Hemalatha Pillai | Promoter Group | Sell | Market Sale | 18000 | 26155310 | 0.00% | XBRL |
| 06 Feb 2025 | Sajitha Pillai | Promoter Group | Sell | Market Sale | 7500 | 11490425 | 0.03% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers ONESOURCE.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
Eroding
ROCE Trajectory
Earnings Quality
Needs net profit and CFO for 3+ stored years; only 1 on file.
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹67.98 Cr. | ₹392.56 Cr. | ₹425.95 Cr. | ₹327.27 Cr. | ₹375.76 Cr. | ₹290.34 Cr. | ₹428.22 Cr. | ₹449.02 Cr. | RevenueFromOperations |
| Net Profit | ₹-39.33 Cr. | ₹-68.85 Cr. | ₹98.20 Cr. | ₹-0.19 Cr. | ₹10.48 Cr. | ₹-88.70 Cr. | ₹4.60 Cr. | ₹25.00 Cr. | ProfitLossForPeriod |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers ONESOURCE.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | -738030000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 114620000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 14259400000.0 |
| CurrentLiabilities | 14419690000.0 |
| EquityAttributableToOwnersOfParent | 58312890000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 12762960000.0 |